DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Campath-1 H (Alemtuzumab)
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2002-06-07

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00038844

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

Not Applicable

Terminated

Conditions: Non Hodgkin's Lymphoma
Aplastic Anemia
Leukemia

Interventions: Procedure: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation

First Posted Date: 2002-06-07

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00038779

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Phase 2

Terminated

Conditions: Pancreatic Neoplasms

Interventions: Drug: TNP-470

First Posted Date: 2002-06-05

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00038701

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Not Applicable

Completed

Conditions: Chronic Myelomonocytic Leukemia
Hypereosinophilic Syndrome
Polycythemia Vera
Mastocytosis
Chronic Myeloid Leukemia

Interventions: Drug: Imatinib Mesylate (Gleevec)

First Posted Date: 2002-06-05

Last Posted Date: 2022-01-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT00038675

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Myelogenous Leukemia, Chronic

First Posted Date: 2002-06-04

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00038597

Locations: 🇺🇸
MDAnderson Cancer Center, Houston, Texas, United States

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Cytarabine
Drug: Mesna
Drug: G-CSF

First Posted Date: 2002-06-04

Last Posted Date: 2015-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00038610

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Phase 2

Terminated

Conditions: Myelogenous Leukemia, Chronic, Chronic Phase

Interventions: Drug: Gleevec

First Posted Date: 2002-06-04

Last Posted Date: 2018-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 117

Registration Number: NCT00038649

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Yttrium-ibritumomab (Zevalin)
Drug: Rituximab

First Posted Date: 2002-06-04

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00038623

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038545

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Phase 3

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Filgrastim SD/01
Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: DTIC

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy